1. Pulse-chase proteomics of the App Knock-In mouse models of Alzheimer’s disease reveals synaptic dysfunction originates in presynaptic terminals
- Author
-
Laith Ali, Jeffrey N. Savas, Tamara Basta, Anis Contractor, Huan Bao, Ewa Bomba-Warczak, Samuel N. Smukowski, Christelle Guillermier, Takashi Saito, Garry Morgan, Charlotte C. M. Castillon, Matthew L. Steinhauser, Arun Upadhyay, Toshihiro Nomura, Edwin R. Chapman, Timothy J. Hark, Nalini R. Rao, Michael H. B. Stowell, Eileen T. O'Toole, and Takaomi C. Saido
- Subjects
Proteomics ,Histology ,Amyloid beta ,Presynaptic Terminals ,Mice, Transgenic ,Biology ,Presynapse ,Article ,Pathology and Forensic Medicine ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Alzheimer Disease ,Genetic model ,Amyloid precursor protein ,Animals ,030304 developmental biology ,0303 health sciences ,Protein turnover ,Long-term potentiation ,Cell Biology ,Cell biology ,Disease Models, Animal ,Proteostasis ,Proteotoxicity ,biology.protein ,030217 neurology & neurosurgery - Abstract
Compromised protein homeostasis underlies accumulation of plaques and tangles in Alzheimer’s disease (AD); however, little is known about the early mechanisms that contribute to this process. To objectively assess protein turnover at early stages of amyloid beta (Aβ) proteotoxicity, we used dynamic (15)N metabolic labeling followed by proteomic analysis of amyloid precursor protein knock in mouse brains. At initial stages of Aβ accumulation, the turnover of proteins associated with presynaptic terminals is selectively impaired. Presynaptic proteins with impaired turnover, particularly synaptic vesicle (SV) associated proteins, have elevated levels, misfold in both a plaque dependent and independent manner, and interact with APP and Aβ. Concurrent with elevated levels of SV associated proteins, we found an enlargement of the SV pool as well as enhancement of presynaptic potentiation. Together, our findings reveal that the presynaptic terminal is particularly vulnerable and represents a critical site for manifestation of initial AD etiology. A record of this paper’s Transparent Peer Review process is included in the Supplemental Information.
- Published
- 2020